Authors: Huang S, Law S, Chen M, Lai H.
DOI: 10.3389/fonc.2025.1728983
Abstract Summary
A 75-year-old woman with HR+/HER2-low advanced breast cancer and large pleural effusion achieved remarkable response to trastuzumab deruxtecan after endocrine therapy failure. Starting at reduced dose due to frailty, then escalating to standard dosing, she experienced near-complete effusion resolution, tumor shrinkage, and 16-month progression-free survival with only mild side effects—no interstitial lung disease.
Why Brain? 🧠
Trastuzumab deruxtecan achieved 16-month disease control with manageable side effects in a frail 75-year-old with HER2-low breast cancer and pleural effusion, supporting its use beyond typical HER2+ cases.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
